Aldosterone synthase (CYP11B2)

Assets acting on this target.

Class
Aldosterone synthase inhibitor

Aldosterone synthase, also known as CYP11B2, is an enzyme found in the outer layer of the adrenal gland (the zona glomerulosa) that produces aldosterone, a hormone that signals the kidney to retain sodium and water while excreting potassium. This process helps regulate blood volume and blood pressure. When aldosterone is produced in excess, either from adrenal tumors or from more diffuse overactivity of the adrenal gland, it drives persistent high blood pressure that often resists standard treatment, and it can independently promote scarring (fibrosis) of the heart and kidney. Inhibiting aldosterone synthase reduces aldosterone production at its source, offering an alternative to blocking the hormone's receptor. This mechanism is being explored mainly for treatment-resistant hypertension, primary aldosteronism, and conditions such as heart failure and chronic kidney disease where aldosterone-driven tissue damage contributes to disease progression. A central design challenge for drugs in this class is achieving selectivity for CYP11B2 over its close molecular relative, CYP11B1, which produces cortisol, the body's principal stress hormone, since unwanted inhibition of cortisol synthesis could cause its own health problems.

By indication

Related mechanisms

Aldosterone synthase (CYP11B2) drugs compared

7 drugs, stage by indication
7 drugs acting on Aldosterone synthase (CYP11B2): developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
BaxdrostatBaxfendyAstraZeneca, Rochesmall moleculeApprovedApproved in Hypertension; Phase 3 in Chronic Kidney Disease; Phase 3 in Heart Failure
LorundrostatMineralys Therapeuticssmall moleculePhase 3Phase 3 in Hypertension; Phase 2 in Chronic Kidney Disease
VicadrostatBoehringer Ingelheimsmall moleculePhase 3Phase 3 in Chronic Kidney Disease; Phase 3 in Heart Failure; Phase 3 in Hypertension; Phase 3 in Type 2 Diabetes
QLS1410Qilu Pharmaceuticalsmall moleculePhase 2Phase 2 in Hypertension
SAL0140Shenzhen Salubris Pharmaceuticalssmall moleculePhase 2Phase 2 in Chronic Kidney Disease; Phase 2 in Hypertension
VB19055Yangli Pharmaceutical Technologysmall moleculePhase 2Phase 2 in Hypertension
JX09Ji Xing Pharmaceuticals (CORXEL)small moleculePhase 1Phase 1 in Hypertension

← all mechanisms